Oncotarget

Meta-Analysis:

Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis

Ling Peng, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Yina Wang and Qiong Zhao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:112076-112084. https://doi.org/10.18632/oncotarget.21057

Metrics: PDF 504 views  |   HTML 864 views  |   ?  


Abstract

Ling Peng1, Yun Hong2, Xianghua Ye3, Peng Shi4,5, Junyan Zhang6, Yina Wang1 and Qiong Zhao1

1Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

2Department of Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

3Department of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

4Department of Medical Statistics, Children’s Hospital of Fudan University, Shanghai, China

5Center for Evidence-Based Medicine, Fudan University, Shanghai, China

6Bothwin Clinical Study Consultant, Seattle, WA, USA

Correspondence to:

Qiong Zhao, email: doczq.2008@hotmail.com

Keywords: eribulin, peripheral neuropathy, incidence, relative risk, meta-analysis

Received: July 10, 2017     Accepted: August 30, 2017     Published: September 19, 2017

ABSTRACT

Background: Eribulin is a microtubule inhibitor, which is approved for the treatment of breast cancer. Peripheral neuropathy has been reported in the studies of eribulin, but the incidence and relative risk (RR) of eribulin-associated peripheral neuropathy varied greatly in cancer patients. The purpose of this meta-analysis was to determine the overall incidence and RR of eribulin-associated peripheral neuropathy in cancer patients.

Materials and Methods: Pubmed database and Embase and abstracts presented at the American Society of Clinical Oncology (ASCO) meetings were systematically reviewed for primary studies. Eligible studies included prospective clinical trials and expanded access programs of cancer patients treated with eribulin. Statistical analyses were performed to calculate the incidences, RRs, and 95% confidence intervals (CIs).

Results: Altogether, 4,849 patients from 19 clinical trials were selected for this meta-analysis. The incidences of all-grade and high-grade peripheral neuropathy were 27.5% (95% CI: 23.3–32.4%) and 4.7% (95% CI: 3.6–6.2%), respectively. The relative risks of peripheral neuropathy of eribulin compared to control were increased for all-grade (RR = 1.89, 95% CI: 1.10–3.25) but not statistically significant for high-grade (RR = 2.98, 95% CI: 0.71–12.42).

Conclusions: The use of eribulin is associated with an increased incidence of peripheral neuropathy. The RR is increased for all-grade peripheral neuropathy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21057